The authors report a case of hormonally silent duodenal somatostatinoma. The main clinical features, the natural history and the currently available therapies of these rare neoplasms are described on the basis of this case and of the scientific literature. Although the antiblastic therapies are still debated, the patient showed a surprising outcome following chemotherapy.
INTRODUCTION
Somatostatinoma is a neuroendocrine neoplasm derived from the D cells of the APUD system firstly described by Pearse1. This tumor is rare and the duodenal location has been described in less than 10 cases. Unlike pancreatic somatostatinoma, described in the late 70's2'3, which generally produces a clinical syndrome (diabetes, steatorrhea, hypochloridria, dyspepsia), duodenal somatostatinoma may be completely asymptomatic.
We report a case of silent duodenal somatostatinoma with hepatic metastases that has been treated by chemotherapy obtaining a surprisingly steady response.
CASE REPORT
The patient was a 43-year-old white woman with a pancreatic pseudocyst previously treated with a cystojejunostomy and a Y-en-Roux gastro-enterostomy and a past history of NANB viral hepatitis. She suffered from dyspepsia for about 1 year. Some months prior to admission the patient had undergone a gastroduodenoscopy because of the onset of post-prandial vomiting and epigastric pain radiating to the back. The endoscopist noticed a patent gastro-enterostomy and a marked dilatation of the duodenal bulb due to a stenosis in the second part of the duodenum.
On admission, the physical examination was completely negative. The general condition and the nutritional status were good. Routine 
CONCLUSIONS
Somatostatinoma is seldom diagnosed preoperatively: physical examination, clinical symptoms and imaging techniques do not give specific results. Duodenal types are generally asymptomatic from the hormonal aspect and may not produce, as in the case we reported, high levels of circulating somatostatin.
The prognosis of resectable somatostatinoma is much better than that described in pancreatic and biliary adenocarcinomas, so the main goal is to achieve, mainly with immunohistochemistry, a correct diagnosis, in order to plan effective surgery. Cytotoxic therapy may be given in diffuse neoplasms with acceptable results.
